TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03313765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Description: Brief MI intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care
Description: Standard-of-care education and counseling
Study: NCT00500110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 30 mg/m\^2 by vein (IV) Weekly Over 60 Minutes on Days 1, 8, 15, and 22. This will be followed by 2 weeks with no docetaxel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: 600 mg by mouth (PO) Daily x 42 Days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Hormone injections given every other month or every 3 months, as determined by the doctor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Hormone injections given every other month or every 3 months, as determined by the doctor.
Study: NCT01691807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab
Description: treatment for NHL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab
Description: treatment for NHL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: treatment for NHL
Study: NCT01691742

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MiraLax
Description: MiraLax 17g powder daily for 5 days postoperatively following urogynecologic surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo maltodextrin 17g powder daily for 5 days postoperatively following urogynecologic surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rescue Laxative
Description: All participants will be instructed to take Milk of Magnesia with standard over-the-counter dosing as a recue laxative if the subject has not had a bowel movement by postoperative day 6.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue Laxative
Description: All participants will be instructed to take Milk of Magnesia with standard over-the-counter dosing as a recue laxative if the subject has not had a bowel movement by postoperative day 6.
Study: NCT03903770

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Upper extremity rehabilitation
Description: Participants receive the SUPER intervention 3 times per week for 1 hr, during 4 weeks. For participants with a low recovery potential for hand function, the SUPER interventions consists in robot-assisted reaching movements and unilateral and bilateral VR activities. The robot-assisted activity consists of a reaching task to six targets placed at maximal reach distance. For the VR activity, we use a reach and grasp VR activity based on a shopping task. Participants with good potential for hand recovery also receive 30 min of electromyography-triggered muscle stimulation, combined with the VR activity. The muscle stimulation is triggered when the participant attempts to grasp a virtual object and helps with hand opening movements.
Study: NCT01279187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: 20ug per day,via subcutaneous injection, for 7 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20ug per day, self administered injection, for 7 weeks
Study: NCT03777176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: Glucagon analog

Intervention type: DRUG
Group type: OTHER
Intervention: Dasiglucagon
Description: Glucagon analog

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care according to site and/or country

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of care according to site and/or country
Study: NCT02434614

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel,Cisplatin,Fluorouracil
Description: Induction chemotherapy: patients receive 60 mg/m2 docetaxel intravenously on day 1, 60 mg/m2 cisplatin intravenously on day 1, and 600 mg/m2/d fluorouracil as a continuous infusion on days 1-5; three cycles were administered at intervals of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel,Cisplatin,Fluorouracil
Description: Induction chemotherapy: patients receive 60 mg/m2 docetaxel intravenously on day 1, 60 mg/m2 cisplatin intravenously on day 1, and 600 mg/m2/d fluorouracil as a continuous infusion on days 1-5; three cycles were administered at intervals of 3 weeks.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated radiation therapy (IMRT)
Description: IMRT is given as 2.0-2.3 Gy per fraction with five daily fractions per week for 6-7 weeks, Cumulative doses were \> 66 Gy to the primary tumor and \> 50 Gy to the bilateral cervical lymph nodes and potential sites of local infiltration.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Description: IMRT is given as 2.0-2.3 Gy per fraction with five daily fractions per week for 6-7 weeks, Cumulative doses were \> 66 Gy to the primary tumor and \> 50 Gy to the bilateral cervical lymph nodes and potential sites of local infiltration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Concurrent chemotherapy: patients received weekly intravenous cisplatin at 30 mg/m2 for 6-7 weeks.
Study: NCT00378560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
Description: V501; Gardasil, 0.5 ml injection in 3 dosing regimen

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo 0.5 ml injection in 3 dosing regimen
Study: NCT03963622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory Mechanics
Description: Different maneuvers based on respiratory mechanics will be assessed at the bedside and will be used to individualize ventilator parameters. Recruitability will be assessed with a one breath decremental PEEP maneuver, and search for airway closure with a low-flow pressure volume or pressure-time curve. If the patient has airway closure, the minimal PEEP will be set at the airway opening pressure to avoid closure. If the patient is considered recruitable, the goal is to set PEEP at or above 15cmH20 to maximize alveolar recruitment, until the plateau pressure reaches the safety limit. Volume control ventilation at 6ml·kg-1 will be used.~Once spontaneous breathing has started, the occlusion pressure (P0.1) will be maintained within targets.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Ventilation Strategy
Description: Patients randomized to the control arm will receive standard care. The PEEP is adjusted for oxygenation based on a PEEP-FiO2 table, either the low PEEP-FiO2 or the high PEEP-FiO2 table. Volume targeted ventilation with initial VT 6 mL·kg-1 and Plateau pressure at 30 cmH2O or below, targeting PaO2 60-80 or SpO2 90-95%, adjusted as per the protocol. Pressure-support ventilation is at physician's discretion, but recommended when FiO2 \<60%, and is titrated VT 6-8 mL·kg-1.
Study: NCT01133977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib tablets administered orally at doses of 16 mg, 20 mg, or 22 mg, once daily continuously over 3 weeks (21 days) during each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 20 mg (MTD/recommended Phase 2 dose as determined in Phase 1b of the study) administered once daily continuously over 3 weeks (21 days) during each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Dacarbazine (1000 mg/m2) infusion over 60 minutes on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazine (1000 mg/m2) infusion over 60 minutes on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazine (1000 mg/m2) infusion over 60 minutes on Day 1 of each 21-day cycle.
Study: NCT01546779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tri-Gym
Description: 40 CF patients performed airway clearance using the VISex, by exhaling against chosen resistance being motivated by visual feedback of raising colored balls. The level of resistance was set to cause longest expiration/volume, until mucus was transported from the peripheral to the central airways, to be expectorated by the subsequent cough.
Study: NCT03439878

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Galactose
Description: Co-ingestion of d-galactose with a high-fat meal

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Co-ingestion of d-glucose with a high-fat meal
Study: NCT01975285

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 0.5% Bupivacaine with 1:200,000 epinephrine + Dexamethasone 4mg per 20cc

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.5% Bupivacaine with 1:200,000epinephrine + Saline 1 ml per 20cc
Study: NCT04719923

Intervention type: BEHAVIORAL
Intervention: Children with autism spectrum disorders
Description: Subjects affected by autism spectrum disorders
Study: NCT04488419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATH-1017
Description: Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe
Study: NCT02557893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Resistance exercise involved 12-weeks of strength training twice per week

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education
Description: Bimonthly pregnancy education classes

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Wait list
Description: Wait list participants were tested on the outcomes during their pregnancy and were eligible to participate in a post-partum supervised exercise program. The wait list participants formed a no treatment control group.
Study: NCT02993341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Wash
Study: NCT04228653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renishaw Drug Delivery System
Description: Device that allows pharmaceuticals to be delivered into the brain is to be assessed over a period of time to inform of the long term safety of the implanted device.
Study: NCT02105870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab
Description: This drug will be administered intracoronary before percutaneous coronary intervention.
Study: NCT00612768

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRUE Test allergens Fragrance Mix and Thimerosol
Description: * Thimerosal, 0.008 mg/cm2 in hydroxypropylcellulose~* Thimerosal, 0.008 mg/cm2 in polyvinylpyrrolidone~* Fragrance mix, 0.43 mg/cm2 in hydroxypropylcellulose with β-cyclodextrin~* Fragrance mix, 0.43 mg/cm2 in polyvinylpyrrolidone with β-cyclodextrin~Patches are placed at day one and removed 48 hours. The duration of the study lasts 21 days. However, the subject is only exposed the the study allergen for 48 hours.
Study: NCT03286803

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliovirus vaccine
Description: we will administer either full dose (0.5ml) or fractional dose (0.1ml) of inactivated poliovirus vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Poliovirus vaccine
Description: we will administer either full dose (0.5ml) or fractional dose (0.1ml) of inactivated poliovirus vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliovirus vaccine
Description: we will administer either full dose (0.5ml) or fractional dose (0.1ml) of inactivated poliovirus vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Poliovirus vaccine
Description: we will administer either full dose (0.5ml) or fractional dose (0.1ml) of inactivated poliovirus vaccine
Study: NCT03994120

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RTMS
Description: Altering the connectivity of trans-synaptic pathways

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RTMS
Description: Altering the connectivity of trans-synaptic pathways

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: RTMS
Description: Altering the connectivity of trans-synaptic pathways
Study: NCT02619812

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serum-derived bovine immunoglobulin/protein isolate (SBI)
Description: SBI 10 grams (The subject will take a total of 4 packets of SBI; taken as two packets of SBI twice a day mixed with water or blended with certain foods)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serum-derived bovine immunoglobulin/protein isolate (SBI)
Description: SBI 10 grams (The subject will take a total of 4 packets of SBI; taken as two packets of SBI twice a day mixed with water or blended with certain foods)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colesevelam
Description: Colesevelam 1.875 g (The subject will take a total of 12 capsules of Welchol 1.875g per day; taken as 6 capsules twice a day by mouth).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colesevelam
Description: Colesevelam 1.875 g (The subject will take a total of 12 capsules of Welchol 1.875g per day; taken as 6 capsules twice a day by mouth).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Double Placebo
Description: Double placebo twice per day (The subject will take a total of 4 packets of placebo and 12 capsules daily taken as 6 capsules twice a day by mouth and two packets of placebo twice a day mixed with water or blended with certain foods).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Double Placebo
Description: Double placebo twice per day (The subject will take a total of 4 packets of placebo and 12 capsules daily taken as 6 capsules twice a day by mouth and two packets of placebo twice a day mixed with water or blended with certain foods).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Double Placebo
Description: Double placebo twice per day (The subject will take a total of 4 packets of placebo and 12 capsules daily taken as 6 capsules twice a day by mouth and two packets of placebo twice a day mixed with water or blended with certain foods).
Study: NCT01576965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fleet Enema (sodium biphosphate and sodium phosphate)
Description: Those assigned to the mechanical bowel prep group will be asked to administer a single sodium phosphate enema rectally before going to bed the night before surgery. If stool is not clear in the morning, mechanical bowel prep subjects will administer one additional enema the morning of surgery
Study: NCT01060969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil and acetazolamide
Description: Experimental arm: Tadalafil 20 mg daily + acetazolamide 125 mg BID beginning above 3000 m altitude.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Active comparator arm (control): acetazolamide 125 mg BID beginning above 3000 m altitude
Study: NCT03476252

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pentraxin 3
Description: serum pentraxin 3 level will be assessed using ELISA kits
Study: NCT00665886

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open Intravenous System - Vasocan®
Description: Vasocan® Safety catheter 18 G x 45 mm (Ref. 4248139S), 20 G x 33 mm (Ref. 4248112S) y 22 G x 25 mm (Ref. 4248090S)with wings and a passive safety mechanism. To the control catheters a three-way tap ('stopcock') with extension tubing 10 cm long (Connecta® Extra 3) from BD (ref 394995)will be added.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed Intravenous System - Nexiva®
Description: BD Nexiva® Catheter (18G x 45 mm, 20 G x 32 mm, 22 G x 25 mm) (Ref. 383609,Ref. 383606,Ref. 383602) BD QSyte®, Ref. 385100 Catheter material is Vialon®. The entire system is Latex and PVC free.
Study: NCT01176994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Formulations for in-vivo fixation
Description: Formulations are comprised of non-toxic ingredients used in dermatology.
Study: NCT00948935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Irinotecan, Panitumumab
Description: Gemcitabine 1000 mg/m2 over 100 minutes(Days 1, 8), irinotecan 100 mg/m2 IV over 60 minutes(days 1, 8) and panitumumab 9 mg/kg IV (day 1) every 3 weeks as a cycle. Continue until disease progression or unacceptable toxicities.
Study: NCT00567801

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional embolectomy/thrombectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: embolectomy/thrombectomy with controlled reperfusion
Study: NCT01545466

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR)
Description: MBSR involves 8 weekly 2 hour classes and one 4-6 hour retreat after the 6th class
Study: NCT02731859

Intervention type: DEVICE
Intervention: Insertion of EndoBarrier for approximately one year
Description: Insertion of EndoBarrier for approximately one year then explantation and follow-up
Study: NCT04447066

Intervention type: OTHER
Intervention: No intervention
Description: No intervention - VHIT will be used but without intervention
Study: NCT04378088

Intervention type: OTHER
Intervention: Validation of CEBuS
Description: Validation of a new score for bubbles in the colon.

Intervention type: OTHER
Intervention: Validation of CEBuS
Description: Validation of a new score for bubbles in the colon.
Study: NCT02577380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPV/GBV HTC
Description: Participants will be interviewed after receiving their services.
Study: NCT01658735

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: H-Wave
Description: Proprietary electrotherapy device using electrical stimulation of unique wave form and energy level that is delivered through transcutaneous electrodes to nerves and soft tissue for analgesic effect.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Electrotherapy device that delivers current at different frequency, amplitude, and wave form through cutaneous electrodes placed near body parts with pain for temporary analgesic effect. The study device is installed inside the same housing as the H-Wave Device and Sham Device, so that all appear the same. There are no identifying marks on the case that participants will recognize in order to maintain blinding.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The sham device is a TENS unit modified to have minimal electrical output. The device is installed in the same housing as the two active arms with equal weight, so that each device in the study appears identical.
Study: NCT06172049

Intervention type: OTHER
Intervention: treatment
Description: the actual treatment CRC patients have reveived
Study: NCT02501785

Intervention type: BEHAVIORAL
Intervention: Caregiver Reaction Assessment (CRA)

Intervention type: BEHAVIORAL
Intervention: The Caregiver Quality of Life - Cancer (CQOLC)
Study: NCT02306785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP05 Coating D
Description: One radio-labelled tablet given to subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP05 Coating E
Description: One radio-labelled tablet given to subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP05 Coating H
Description: One radio-labelled tablet given to subjects
Study: NCT04385836

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alpha one antitrypsin inhalation
Description: - we will give 8 ml of intravenous alpha one antitrypsin (alpha1-proteinase inhibitor (AATD)Glassia 50 ml) as nebulizer every 12 hours for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: alpha one antitrypsin inhalation
Description: - we will give 8 ml of intravenous alpha one antitrypsin (alpha1-proteinase inhibitor (AATD)Glassia 50 ml) as nebulizer every 12 hours for 5 days
Study: NCT02994277

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1° Phase: UVa algorithm 2° Phase: ITBA/UNLP algorithm
Description: The UVa algorithm is an already established mathematical model that can be programmed in DiAs software to manage glycaemia in T1DM through a subcutaneous insulin pump and a continous glucose monitoring. This algorthm works on a meal announcement basis and will be tested during the first phase of the trial. The ITBA/UNLP algorithm is a new development with safety mechanisms improved and without need of meal anouncement. This algorithm will be tested during the second phase of the trial.
Study: NCT02520947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIS
Description: Bispectral index monitoring

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: volatile agent for maintenance of anesthesia

Intervention type: DRUG
Group type: OTHER
Intervention: Desflurane
Description: volatile agent for maintenance of anesthesia
Study: NCT03407911

Intervention type: OTHER
Intervention: Harvested
Description: Metagenomic exam of Gingival crevicular fluid harvested by adsorbent paper point around periodontal teeth and implant affected by peri-implantitis

Intervention type: OTHER
Intervention: Harvested
Description: Metagenomic exam of Gingival crevicular fluid harvested by adsorbent paper point around periodontal teeth and implant affected by peri-implantitis

Intervention type: OTHER
Intervention: Harvested
Description: Metagenomic exam of Gingival crevicular fluid harvested by adsorbent paper point around periodontal teeth and implant affected by peri-implantitis
Study: NCT00621322

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: GSK Biologicals' AS01B adjuvant
Description: Intramuscular injection, 2 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 1
Description: Intramuscular injection, 2 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 2
Description: Intramuscular injection, 2 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 3
Description: Intramuscular injection, 2 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 1
Description: Intramuscular injection, 2 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 2
Description: Intramuscular injection, 2 doses